The monoclonal antibody developer took its total funding to about $220m since 2010 in a round that included Shenzhen Hepalink and Malin Corporation.
UK-based antibody developer Kymab raised $100m yesterday in a series C round featuring pharmaceuticals producer Shenzhen Hepalink and life sciences company Malin Corporation.
The round was led by Ori Healthcare Fund, a China-based venture capital fund launched by former Goldman Sachs bankers and healthcare scientists, and included Wellcome Trust, Bill & Melinda Gates Foundation, CF Woodford Equity Income Fund and Woodford Patient Capital.
Kymab is working on humanised antibodies based on its Kymouse antibody platform to treat cancer and other…
